About us

IS Pharma plc (AIM:ISPH) is a fast growing specialist hospital medicines group, which is traded on the Alternative Investment Market ("AIM").

The strategy of the Group is to grow by combining the acquisition of products and companies with the dynamic development and marketing of these assets. With a focus in the specialist hospital sector, IS Pharma leverages its expertise in both pharmaceuticals and medical devices to drive growth.

Based in the UK, IS Pharma commercialises its portfolio in the UK directly. IS Pharma also operates internationally through a strong network of distributors. Currently focused in the areas of critical care, neurology and oncology, IS Pharma's marketed and development brands include:

Critical Care: Volplex^® (succinylated gelatin, plasma substitute), Cryogesic^®/Dermogesic^® (cryo-analgesic), Haemopressin^® ( treatment of oesophageal varices), ISOplex^® (isotonic plasma substitute), AquiHex^® (anti bacterial).

Neurology: Mysoline^® (primidone), a product currently used to treat Epilepsy and which IS Pharma are developing for management of Essential Tremor, a distressing condition affecting an estimated 1 in 25 over 40 year olds for which primidone is one of only two recommended treatments, Acoranil^® (anti depressant syrup).

Oncology: Aloxi^® (treatment of chemotherapy induced nausea and vomiting), 5 FU (an oral chemotherapeutic agent for the treatment of cancer) and Cryogesic^®.

Products which are outside of the Group's core hospital focus or are in early stage of research are out-licensed, including the successful OptiFlo^™ Catheter Maintenance Solutions (to Bard Limited) and micelle nanotechnology, which is incorporated into an early stage lidocaine based product for the treatment of interstitial cystitis (to Plethora Solutions Limited).

OptiFlo™ is a trademark of CR.Bard Inc or an affiliate.